CompanyPlaceholder
ARYAN AI secures $3M to expand its wet-lab validation loop
New funding strengthens the connection between our models and the bench, adding assay capacity so every design cycle is tested faster.
Investors
Investors
Driving long-term value through scientific innovation — a platform that compounds with every experiment, and a pipeline built on human biology.
- Total funding raised
- $3M
- Active discovery programmesPlaceholder
- 8
- Experimental success rate*
- 76%
* Share of AI-prioritised hypotheses confirmed in first-round wet-lab validation (owner-reported).
Investment case
Why ARYAN AI
Two sources of value
Proprietary programmes and partnered projects built on the same platform.
Capital-efficient discovery
In silico filtering reduces the number of costly experiments per candidate.
Defensible platform
Proprietary data from our own lab loop improves the models over time.
Status
A private company
ARYAN AI Drug Discovery is privately held. To date the company has raised $3M in total funding.
Materials for qualified investors, including our data room, are available on request under a confidentiality agreement. Nothing on this website is an offer of securities.
News & Insights
Latest from ARYAN AI
PartneringPlaceholder
ARYAN AI opens partnering for target-discovery and co-development projects
We are inviting academic groups, biotech companies and pharmaceutical partners to collaborate on target discovery, molecule design and joint programmes.
SciencePlaceholder
Why we report our experimental success rate — and how we define it
AI in drug discovery is only meaningful when predictions are tested. We explain the metric we track and why transparency about definitions matters.